G-45

Dosage for Vitis Vinifera Flowering Top is highly individualized and is not standardized across different manufacturers. Healthcare providers use a 'serial dilution' strategy.

• Diagnostic Testing: For skin prick testing, a single drop of the 1:10 or 1:20 w/v extract is applied to the skin, followed by a puncture. For intradermal testing, 0.02 mL to 0.05 mL of a highly dilute solution (e.g., 1:1000 w/v) is injected into the dermis.
• Immunotherapy Build-up Phase: Treatment usually begins with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution). Injections are given 1–2 times per week, with the dose increasing by 50% to 100% at each visit, provided the patient tolerates the previous dose without a significant local or systemic reaction.
• Maintenance Phase: Once the 'maintenance dose' is reached (the highest dose tolerated by the patient that provides symptomatic relief), the interval between injections is increased to every 2–4 weeks.

There is no specific age-based dosage for children. Pediatric patients typically follow the same titration (dose-escalation) schedule as adults, but the starting dose may be even more conservative based on the child's sensitivity level and the physician's discretion. Safety and effectiveness in children under the age of 5 have not been extensively established in controlled clinical trials, though allergenic extracts are frequently used in this population under expert supervision.

Renal Impairment

No specific dosage adjustments are required for patients with kidney disease, as the systemic load of the extract is extremely low. However, the patient's overall health must be stable.

Hepatic Impairment

No dosage adjustments are formally recommended for liver impairment. The metabolic clearance of these proteins is not primarily dependent on hepatic CYP450 enzymes.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The risk of using epinephrine (the treatment for a severe reaction) in patients with heart conditions must be weighed against the benefits of the extract.

• Administration: This product must NEVER be self-administered. It must be injected or applied by a healthcare professional in a clinical setting equipped with emergency resuscitation equipment.
• Observation: Patients must remain in the doctor's office for at least 30 minutes following any injection or skin test to monitor for signs of anaphylaxis (a life-threatening allergic reaction).
• Site of Injection: Subcutaneous injections for immunotherapy are typically given in the posterior aspect of the upper arm.
• Storage: Extracts should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Freezing can denature the proteins and render the extract ineffective or dangerous.

If a dose of immunotherapy is missed, the next dose may need to be reduced depending on how much time has passed.

• If 1 week is missed: The previous dose may be repeated.
• If 2–4 weeks are missed: The dose is usually reduced by one or more increments to prevent a systemic reaction due to a loss of tolerance.
• If more than 4 weeks are missed: The build-up process may need to be restarted from a much lower concentration.

An 'overdose' in the context of allergenic extracts usually refers to an injection of a concentration higher than what the patient's current tolerance level allows.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, low blood pressure, or abdominal cramping.
• Management: Immediate administration of epinephrine (adrenaline), oxygen, intravenous fluids, and antihistamines. Emergency medical services must be contacted immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.

Most patients receiving Vitis Vinifera Flowering Top will experience some form of localized reaction. These are generally considered expected and manageable.

• Local Wheal and Flare: During diagnostic testing, a red, itchy bump is the intended result. This usually fades within 2–4 hours.
• Injection Site Swelling: In immunotherapy, a 'local reaction' involving redness and swelling at the injection site (up to the size of a half-dollar) is common. This may feel warm to the touch and itchy (pruritus).
• Mild Fatigue: Some patients report feeling tired for a few hours following an immunotherapy session.

• Large Local Reactions (LLR): Swelling that exceeds 5–10 cm in diameter at the injection site. This may persist for 24–48 hours and can be treated with cold compresses and oral antihistamines.
• Generalized Pruritus: Itching that occurs away from the site of injection, such as on the palms of the hands or the scalp.
• Nasal Congestion: A mild 'flare-up' of hay fever symptoms shortly after the injection.

• Systemic Urticaria: Hives appearing all over the body.
• Angioedema: Significant swelling of the deeper layers of the skin, often around the eyes or lips.
• Persistent Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the armpit).

> Warning: Stop taking Vitis Vinifera Flowering Top and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Shortness of breath, wheezing, or a high-pitched sound when breathing (stridor).
• Throat Tightness: A feeling that the throat is closing or difficulty swallowing (dysphagia).
• Hypotension: A sudden drop in blood pressure, which may feel like dizziness, lightheadedness, or fainting (syncope).
• Gastrointestinal Distress: Severe abdominal cramps, vomiting, or diarrhea occurring within minutes of the injection.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.

There are no known long-term 'toxic' effects of Vitis Vinifera Flowering Top, as it is a biological protein extract. However, there is a theoretical risk of developing new sensitivities to other components in the extract over several years of treatment, although this is clinically rare. Some patients may develop 'subcutaneous nodules' (small, hard bumps under the skin) at the site of repeated injections, which are usually benign.

While Vitis Vinifera Flowering Top may not have a specific individual black box warning for the brand, the entire class of Allergenic Extracts carries a general FDA-mandated warning regarding Anaphylaxis.

Summary of Warning: Allergenic extracts can cause severe, life-threatening systemic reactions, including anaphylaxis. Patients with unstable asthma are at a higher risk for fatal outcomes. Injections must be administered in a facility where the patient can be monitored and where emergency medications (epinephrine) and equipment are immediately available. Patients should be instructed to recognize the signs of a delayed systemic reaction and seek emergency care if one occurs after leaving the clinic.

Report any unusual symptoms to your healthcare provider.

Vitis Vinifera Flowering Top is intended only for use by physicians experienced in the diagnosis and treatment of allergic diseases. Because of the risk of severe systemic reactions, certain safety protocols are mandatory. Patients must be screened for current health status (e.g., checking for active asthma symptoms) before every single injection.

No FDA black box warnings specifically for 'Vitis Vinifera Flowering Top' as a standalone entity, but it falls under the mandatory class warning for all allergenic extracts regarding the risk of severe anaphylaxis. This warning emphasizes that extracts should not be injected intravenously and that patients must be observed for at least 30 minutes post-administration.

• Allergic Reactions / Anaphylaxis Risk: This is the primary risk. Anaphylaxis can occur even in patients who have previously tolerated the extract without issue. The risk is higher during the build-up phase and when switching to a new vial of extract.
• Asthma Stability: Patients with poorly controlled or unstable asthma should not receive Vitis Vinifera Flowering Top injections. Severe bronchial constriction is a major component of fatal allergic reactions.
• Cardiovascular Disease: Patients with significant heart disease may be at higher risk because they may not tolerate the physiological stress of a systemic reaction or the effects of the epinephrine used to treat it.
• Beta-Blocker Use: Patients taking beta-blockers (medications for blood pressure or heart rate) may be resistant to the effects of epinephrine, making a systemic reaction much harder to treat.

• Peak Flow Meter: For asthmatic patients, a peak flow reading may be taken before the injection to ensure lung function is at its baseline.
• Observation Period: A mandatory 30-minute wait in the clinic after every dose.
• Vital Signs: Blood pressure and heart rate monitoring if a reaction is suspected.
• Skin Inspection: The injection site must be inspected for local reactions before the patient is discharged.

Generally, Vitis Vinifera Flowering Top does not cause drowsiness. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have been fully cleared by a medical professional.

There is no direct chemical interaction between alcohol and the extract. However, alcohol consumption can cause vasodilation and may theoretically increase the rate of absorption of the extract or mask the early symptoms of an allergic reaction. Patients are often advised to avoid alcohol for several hours after an injection.

Unlike many medications, there is no 'withdrawal syndrome' associated with stopping Vitis Vinifera Flowering Top. However, stopping immunotherapy prematurely will result in the return of allergy symptoms, as the immune system has not been fully desensitized.

> Important: Discuss all your medical conditions with your healthcare provider before starting Vitis Vinifera Flowering Top.

There are few absolute contraindications for drug combinations, but the following are critical:

• Beta-Blockers (Non-selective and Selective): While not strictly 'contraindicated' in all guidelines, many allergists will not perform immunotherapy on patients taking beta-blockers (e.g., propranolol, atenolol, metoprolol). The clinical consequence is that beta-blockers block the receptors that epinephrine needs to work. If the patient has anaphylaxis, the life-saving 'antidote' (epinephrine) may fail to work, leading to a fatal outcome.

• ACE Inhibitors: Some studies suggest that patients on ACE inhibitors (e.g., lisinopril, enalapril) may have more frequent or more severe systemic reactions to allergenic extracts. The mechanism involves the inhibition of the breakdown of bradykinin, a potent vasodilator.
• MAO Inhibitors (MAOIs): Medications used for depression (e.g., phenelzine) can potentiate the effects of epinephrine, leading to a hypertensive crisis (dangerously high blood pressure) if epinephrine is administered for an allergic reaction.
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs (e.g., amitriptyline) can increase the cardiovascular response to epinephrine.

• Antihistamines: Drugs like cetirizine (Zyrtec), loratadine (Claritin), and diphenhydramine (Benadryl) will suppress the skin's response to the extract. For diagnostic testing, these must be discontinued 3–7 days in advance. For immunotherapy, they are sometimes used to manage local reactions, but they can mask the early warning signs of a systemic reaction.
• Topical Corticosteroids: Applying steroid creams to the testing site can suppress the wheal and flare reaction, leading to a false-negative diagnostic result.

• Grape and Wine Consumption: Patients highly sensitive to Vitis vinifera may experience 'oral allergy syndrome' (itching in the mouth) when eating grapes. While this doesn't interact with the extract itself, patients should avoid new or highly allergenic foods on the day of their injection to avoid confusing a food allergy with a reaction to the shot.

• St. John's Wort: May theoretically affect the metabolism of medications used to treat anaphylaxis, though this is not well-documented.
• Feverfew/Ginkgo: These supplements have mild anti-platelet or anti-inflammatory effects that could theoretically alter the skin's inflammatory response during testing.

• Skin Testing Results: The extract itself is the test. However, the presence of the extract in the system does not typically interfere with standard blood labs (CBC, metabolic panels).
• Total IgE: Immunotherapy may cause a transient rise in total IgE levels before they eventually decrease over several years.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe, Uncontrolled Asthma: Patients whose asthma is not well-managed (FEV1 consistently below 70% of predicted) are at an unacceptably high risk of a fatal respiratory reaction to allergenic extracts.
• Previous Life-Threatening Reaction: If a patient has previously experienced a near-fatal reaction to Vitis Vinifera Flowering Top, further use is typically contraindicated.
• Acute Infection: Injections should not be given if the patient has a fever or a significant respiratory infection, as this can lower the threshold for a systemic allergic reaction.

• Pregnancy (Initiation): It is generally recommended NOT to start a new course of Vitis Vinifera Flowering Top immunotherapy during pregnancy due to the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen to the baby). However, if a woman is already on a maintenance dose and tolerating it well, the treatment may be continued.
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may have unpredictable immune responses to immunotherapy.
• Malignancy: Patients with active cancer may have altered immune systems that make immunotherapy less effective or more risky.

Patients who are allergic to Vitis Vinifera Flowering Top may also show sensitivity to other members of the Vitaceae family. There is also a known phenomenon called 'pollen-food syndrome' where patients allergic to certain plant pollens may react to related fruits. Cross-reactivity between grapevine components and other viticultural products (like certain types of raisins or grape-seed extracts) is possible.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Vitis Vinifera Flowering Top.

Vitis Vinifera Flowering Top is generally classified as Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known if the extract can cause fetal harm. The primary concern is not the extract itself, but the potential for maternal anaphylaxis. If the mother's blood pressure drops or she stops breathing, the fetus is at immediate risk of death or brain damage. Therefore, dose escalation (the build-up phase) is usually avoided during pregnancy.

It is not known whether the allergenic components of Vitis Vinifera Flowering Top are excreted in human milk. However, because these are large proteins that are likely digested in the infant's gut, the risk to a nursing infant is considered very low. Breastfeeding is generally not a reason to discontinue immunotherapy.

As noted, immunotherapy is common in children but requires expert management. Children may have more difficulty communicating the early symptoms of a systemic reaction (like an 'itchy throat' or 'feeling of doom'), so they must be watched very closely. The benefits of immunotherapy in children include the potential to prevent the development of asthma and new allergies later in life.

In patients over age 65, the decision to use Vitis Vinifera Flowering Top must involve a careful cardiovascular assessment. Older adults are more likely to be taking medications (like beta-blockers) that complicate allergy treatment. Furthermore, the physiological 'reserve' to survive a severe systemic reaction is often lower in the elderly.

There is no evidence that renal impairment alters the safety of Vitis Vinifera extracts. The dose is not systemic enough to require GFR-based adjustments.

No specific studies have been performed in patients with liver failure. However, since the proteins are degraded by general proteases throughout the body, hepatic impairment is not expected to significantly alter the drug's profile.

> Important: Special populations require individualized medical assessment.

Vitis Vinifera Flowering Top acts as an exogenous (external) antigen. In sensitized individuals, it binds to specific IgE antibodies on the surface of mast cells and basophils. This binding causes the 'cross-linking' of the FceRI receptors, leading to an influx of calcium into the cell and the subsequent release of pre-formed mediators like histamine, proteoglycans, and serine proteases. It also triggers the synthesis of newly formed mediators like leukotrienes and prostaglandins.

The pharmacodynamic effect is measured by the 'Wheal and Flare' response. The Wheal (edema) is caused by increased capillary permeability, while the Flare (redness) is caused by a neural reflex (the 'axon reflex') that leads to vasodilation in the surrounding area. The maximum response typically occurs within 15–20 minutes of exposure. In immunotherapy, the pharmacodynamic goal is the long-term reduction of the IgE/IgG4 ratio.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Local/Subcutaneous) |

| Protein Binding | N/A (Biological Protein) |

| Half-life | Variable (Hours for proteins) |

| Tmax | 15–20 minutes (Skin reaction) |

| Metabolism | Local Proteolysis |

| Excretion | Renal (Metabolites) |

• Molecular Formula: N/A (Complex biological mixture)
• Molecular Weight: Ranges from 10 kDa to 70 kDa (Typical for plant allergens)
• Solubility: Soluble in aqueous buffers and saline/glycerin mixtures.
• Description: A clear to slightly amber liquid extract containing the water-soluble proteins of the Vitis vinifera flower.

Vitis Vinifera Flowering Top is a Non-Standardized Plant Allergenic Extract. It belongs to the therapeutic class of Allergenic Biologicals. Related medications include extracts for Timothy Grass, Ragweed, and various tree pollens, though each is specific to its own botanical source.